Clearside Biomedical announced the appointment of Thomas A. Ciulla, MD, MBA, to the position of Chief Medical Officer.
A board certified ophthalmologist and retinal specialist, Dr. Ciulla brings more than 27 years of clinical practice, academic, and executive management experience within the global ophthalmic industry to Clearside. Prior to joining Clearside, Dr. Ciulla served as Vice President, Ophthalmic Strategy Lead at Spark Therapeutics. In that role, among other accomplishments, he defined and led medical strategy to support development and commercialization of Luxturna (voretigene neparvovec-rzyl), the first FDA-approved gene therapy for a genetic disease.
Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research laboratory at Indiana University School of Medicine, the largest U.S. medical school. Today, he remains a volunteer Clinical Professor of Ophthalmology at the university and also serves on the Board of Directors of Midwest Eye Institute. Dr. Ciulla is an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, American Society of Retina Specialists, and the American Academy of Ophthalmology.
Dr. Ciulla has held numerous leadership roles in clinical research, including principal investigator, medical monitor, and member of scientific advisory, data safety monitoring or writing committees in over 100 national clinical trials, including CATT and registration trials for nearly all retinal therapeutics currently approved by the FDA. He has served on journal editorial boards, edited several textbooks, presented at over 200 conferences, and co-authored over 200 publications, including the first published U.S.-based randomized clinical trial on any intravitreal therapy in neovascular AMD. Dr. Ciulla graduated from Harvard College and UCSF Medical School, followed by an internship and residency at Harvard Medical School, and a fellowship at Tufts Medical School. He also earned an MBA from Indiana University’s Kelley School of Business, specializing in the business of medicine.
“In addition to being a skilled ophthalmologist and retinal specialist, Tom is well recognized for his ability to serve as a strong liaison between ophthalmic biopharmaceutical developers and their stakeholders, as well as for his passionate commitment to ensuring clinical programs are designed to meet the needs of both clinicians and patients,” Clearside’s Chief Executive Officer and President, Daniel White said in a company news release. “I have great confidence that he will play a key role in the continued advancement of both our late-stage pipeline and our non-clinical programs in areas such as gene therapy and choroidal drug delivery.”